Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare

Author:

Ribeiro Emmanuel1,Cressend Thomas1,Duffau Pierre2,Grenouillet-Delacre Marieke1,Rouanet-Larivière Marie3,Vital Anne45,Longy-Boursier Maïté1,Mercié Patrick1

Affiliation:

1. Service de Médecine Interne, Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

2. Service de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France

3. Service d'Exploration Fonctionnelle du Système Nerveux, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

4. Laboratoire d'Anatomo-Pathologie, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

5. Université Victor-Segalen Bordeaux 2, 146, rue Léo-Saignant, 33076 Bordeaux Cedex, France

Abstract

Polyarteritis nodosa (PAN) is a systemic vasculitis whose severe forms are treated with glucocorticoids and cyclophosphamide. Refractory patients are exposed to many complications, notably accelerated atherosclerosis. We report a case report of 71-year-old man followed for polyarteritis nodosa refractory to glucocorticoids and cyclosphosphamide. Systemic vasculitis relapses are followed to accelerated atherosclerosis: severe ischemic lesions led to amputation of lower limbs. Remission of refractory PAN is obtained with rituximab. Disappearance of biological inflammatory is allowed to regression of ischemic lesions in upper limbs. In this situation, we recommend a systematic vascular work-up for patients suffered from refractory vasculitis. On the other hand, therapeutic trials are needed to determine the real efficacy and place of rituximab in the treatment of polyarteritis nodosa.

Publisher

Hindawi Limited

Subject

General Medicine

Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Polyarteritis Nodosa: Old Disease, New Etiologies;International Journal of Molecular Sciences;2023-11-23

2. Steroid sparing in vasculitis: Myth or reality?;Best Practice & Research Clinical Rheumatology;2023-03

3. Efficacy of rituximab in refractory polyarteritis nodosa: a case report;Pan African Medical Journal;2023

4. Cardiac involvement and cardiovascular risk factors in pediatric primary systemic vasculitides;Clinical Rheumatology;2022-11-12

5. Off-Label Uses of Rituximab in Dermatology;Current Dermatology Reports;2022-10-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3